Jazz Pharmaceuticals plc
Jazz Pharmaceuticals Appoints New Chief Financial Officer
Summary
Jazz Pharmaceuticals plc announced on February 21, 2024, the appointment of Philip Johnson as Executive Vice President and Chief Financial Officer, effective March 1, 2024. Mr. Johnson, with over 35 years of financial experience, succeeds Patricia Carr, who has been serving as the interim principal financial officer. Previously, Mr. Johnson served as Group Vice President of Finance, Treasurer, at Eli Lilly and Company. His compensation includes an annual base salary of $700,000, a signing bonus of $150,000, participation in various benefit and compensatory plans, and a new hire equity grant valued at approximately $4,000,000. A press release announcing the appointment was also furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Profitelligence Alerts
Get alerts for JAZZ
Be first to know when Jazz Pharmaceuticals plc files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company that focuses on developing life-changing medicines for patients in various therapeutic areas. The company's primary function is to research, manufacture, and market drugs that address unmet medical needs, particularly in the fields of neuroscience, oncology, and sleep medicine. Jazz Pharmaceuticals has gained prominence for its innovative products such as Xyrem, used for treating narcolepsy, and Vyxeos, a treatment for certain types of leukemia. Headquartered in Dublin, Ireland, the company operates extensively across North America and Europe, working to advance scientific research in pharmaceuticals. By prioritizing patient care and survival, Jazz Pharmaceuticals plays a significant role in the pharmaceutical industry with its commitment to developing novel therapies. Moreover, the company's strategic collaborations and acquisitions enable it to expand its product portfolio and impact the healthcare sector positively. Jazz Pharmaceuticals continues to be a key player in transforming patient care for complex conditions.
Official SEC Documents
Advertisement